Media headlines about Raptor Pharmaceutical Corp (NASDAQ:RPTP) have been trending positive on Tuesday, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Raptor Pharmaceutical Corp earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.4491738886128 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Raptor Pharmaceutical Corp (NASDAQ RPTP) remained flat at $9.00 during trading on Tuesday.
About Raptor Pharmaceutical Corp
Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.
Receive News & Ratings for Raptor Pharmaceutical Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp and related companies with MarketBeat.com's FREE daily email newsletter.